Zepbound vs. Tirzepatide: What You're Actually Choosing Between

Is Zepbound the same thing as tirzepatide?

Yes, fully. Tirzepatide is the active molecule. Zepbound is Eli Lilly's brand name for it, FDA-approved in 2023 specifically for chronic weight management. The same molecule is also sold under a second brand name, Mounjaro, approved for type 2 diabetes — same injection, same active ingredient, different indication and different packaging. There's no clinical trade-off to weigh between "Zepbound" and "tirzepatide" the way you'd weigh two different drugs, because they aren't two different drugs.

The comparison that actually matters, and the one most people typing this search are really asking about, is Zepbound versus compounded tirzepatide: the FDA-approved brand-name injection from Lilly, against a pharmacy-mixed version of the same active ingredient sold through cash-pay telehealth. That's the comparison this page walks through.

What actually separates Zepbound from compounded tirzepatide?

Zepbound went through FDA review as a finished drug — the agency evaluated Lilly's manufacturing process, sterility controls, and dose-to-dose consistency before it reached pharmacy shelves. Compounded tirzepatide is prepared by a licensed 503A pharmacy under state pharmacy law, using tirzepatide the pharmacy sources itself. It has not gone through that same finished-product review. That's the concrete meaning behind the phrase "not FDA-approved as a finished drug": the compounding pharmacy isn't required to demonstrate the same manufacturing consistency or sterility testing that Lilly's plants undergo for Zepbound.

Some compounded formulas also add ingredients Zepbound doesn't contain — commonly vitamin B12, glycine, or L-carnitine, marketed as supporting energy or absorption. Eli Lilly, in an open letter to patients and providers, says its own testing of compounded tirzepatide-plus-B12 products turned up bacterial contamination, high endotoxin levels, and impurities not present in Zepbound or Mounjaro — worth reading with the caveat that Lilly has an obvious commercial stake in steering patients toward its own brand. Neither claim changes the underlying fact: additives haven't been studied in combination with tirzepatide the way the base molecule has been.

Zepbound vs. compounded tirzepatide: which costs less?

Compounded is cheaper at the entry tier, but the gap is smaller than it used to be. Curex currently has the lowest verified all-in price for compounded tirzepatide, and LillyDirect's starter-dose self-pay price for brand-name Zepbound sits only about $100 above it. As doses climb, LillyDirect's flat $449 ceiling for 7.5mg through 15mg often lands close to or below several compounded programs' higher tiers — Willow's price rises with dose, for instance, while LillyDirect's does not past 7.5mg.

• Curex — cheapest verified compounded price, all-in with no separate membership; the $199 figure is a starter-dose rate.
• Mochi Health — flat $199 medication at every dose, but a separate membership brings the real total closer to $278.
• Henry Meds — the oral tablet and the injection are priced separately, and it's one of very few providers offering a pill at all.
• Willow — a single flat price at each dose tier, rising as you titrate up, available in about 33 states.
• LillyDirect — the brand option, priced in three tiers by dose, with a 45-day refill window that resets pricing higher if missed.

For the full breakdown of every compounded provider, including ones not featured here, see compounded tirzepatide and tirzepatide cost. If you're specifically weighing cash-pay routes with no insurance at all, tirzepatide without insurance lays out every pathway side by side, and cheapest tirzepatide ranks the lowest verified prices we track.

Is compounded tirzepatide still legal and safe right now?

Legal, but on a narrower basis than during the 2022–2024 shortage years. Once the FDA declared the tirzepatide shortage resolved in December 2024, large-scale 503B compounding lost its legal footing — enforcement discretion for 503B outsourcing facilities ended in March 2025. What remains is the 503A individual-patient pathway: a licensed pharmacy compounding tirzepatide for a specific, named patient with a documented clinical reason the FDA-approved version won't work for them. Cost alone isn't a qualifying reason under current FDA guidance, even though cost is the reason most patients are drawn to it.

There's a pending regulatory question layered on top. On April 30, 2026, the FDA proposed excluding tirzepatide, along with semaglutide and liraglutide, from the 503B bulk drug substances list — a step that would formalize what's already happened in practice since 2025. That comment period, extended through July 30, 2026, remains open as of this writing; no final rule has been issued, and it wouldn't change 503A rules even once it does.

Separately, and worth knowing directly: Eli Lilly sued several telehealth compounders in 2025, including Mochi Health, Henry Meds, and Willow — three of the providers priced on this page. The suits center on marketing claims and, for Henry Meds specifically, on the safety of its oral tirzepatide tablet, which Lilly argues has never been tested in a clinical trial the way an oral drug normally would be. None of the suits allege these pharmacies aren't dispensing real tirzepatide; the disputes are about how the products are marketed and formulated. As of mid-2026 the cases are ongoing and unresolved, which is itself a fact worth weighing before you enroll.

Tirzepatide tablets vs. injections — does Zepbound come as a pill?

No. Zepbound is injection-only, sold either as a single-dose vial you draw with a syringe or a prefilled KwikPen autoinjector — there's no FDA-approved oral tirzepatide on the market. That's a structural limitation, not a marketing choice: tirzepatide is a peptide, and unmodified peptides generally don't survive digestion intact, which is why an oral version needs special formulation work to reach the bloodstream at all.

Henry Meds is one of the few compounded providers selling tirzepatide as a dissolving oral tablet, which is the real differentiator for anyone who wants to avoid needles entirely. It's also, as noted above, the specific product Eli Lilly's lawsuit challenges — the company's position is that no clinical study has established oral tirzepatide's safety or absorption the way Novo Nordisk did for Rybelsus, its FDA-approved oral semaglutide tablet, which uses a specific absorption-enhancing formulation. If a pill over a needle is a hard requirement and you want to see how oral semaglutide compares on that front, semaglutide vs tirzepatide covers that ground directly.

Zepbound or compounded tirzepatide — which is right for you?

• You want FDA-approved manufacturing and can manage the refill discipline → LillyDirect. The self-pay tiers start close to compounded pricing, and the product has gone through the same review as any other approved drug — you just need to refill within the 45-day window to hold the rate.
• Cost is the binding constraint → compounded, starting with Curex's all-in starter price. Understand it as a legally and clinically distinct product from Zepbound, not a discount version of the same thing.
• You want a pill, not a needle → Henry Meds is the only route to an oral tirzepatide tablet right now, with the caveat that its safety is currently disputed in litigation rather than settled by an FDA review.
• You have insurance that covers obesity treatment, or want a savings-card path → Zepbound only. Compounded tirzepatide has no insurance or manufacturer savings-card pathway at all — it's cash-pay by definition.
• You're not sure your provider is legitimate → ask directly which 503A pharmacy fills the prescription, whether it's PCAB-accredited, and how the clinician documents your specific clinical need — that standard applies to every compounded option on this page.

What about Ozempic, Mounjaro, or retatrutide — should you be comparing those instead?

A few adjacent searches land here by accident, so briefly: if you're actually weighing a different GLP-1 molecule against tirzepatide, not brand-versus-compounded of the same drug, these are the real comparisons.

• Ozempic (semaglutide) is a genuinely different molecule, not a brand name for tirzepatide — see semaglutide vs tirzepatide for the actual head-to-head on efficacy, side effects, and price.
• Mounjaro is the same molecule as Zepbound, approved for type 2 diabetes rather than weight management, with its own separate savings-card and self-pay pricing — same drug, different brand and different indication, not a real "versus."
• Retatrutide is a distinct, newer molecule that adds a third receptor target beyond tirzepatide's two — it remains investigational, in Phase 3 trials, with no FDA approval and no established pricing or access landscape as of mid-2026, so it isn't yet a real alternative to weigh against either Zepbound or compounded tirzepatide.